LSTA — Lisata Therapeutics Share Price
0.000.00%
Last trade - 00:00- $18.06m
- -$13.44m
- $1.00m
- 24
- 28
- 27
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.61 | ||
| Price to Tang. Book | 0.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76.25% | ||
| Return on Equity | -51.43% | ||
| Operating Margin | -2240.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 1 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Directors
- Gregory Brown NEC (67)
- David Mazzo PRE (64)
- Todd Girolamo SVP (55)
- William Sietsema VPR (65)
- Michael Davidson IND (64)
- Steven Klosk IND (64)
- Steven Myers IND (74)
- Cynthia Schwalm IND (61)
- Peter Traber IND (66)
- Anne Whitaker IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 18th, 1980
- Public Since
- November 3rd, 1995
- No. of Shareholders
- 291
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 8,598,204
- Address
- 110 Allen Road, Second Floor, BASKING RIDGE, 07920
- Web
- https://www.lisata.com/
- Phone
- +1 9082292590
- Contact
- John Menditto
- Auditors
- Grant Thornton LLP
Upcoming Events for LSTA
Lisata Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Lisata Therapeutics Inc Earnings Release
Q3 2025 Lisata Therapeutics Inc Earnings Release
Similar to LSTA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Lisata Therapeutics share price?
As of Today at 21:46 UTC, shares in Lisata Therapeutics are trading at $2.10. This share price information is delayed by 15 minutes.
How has the Lisata Therapeutics share price performed this year?
Shares in Lisata Therapeutics last closed at $2.10 and the price had moved by -27.91% over the past 365 days. In terms of relative price strength the Lisata Therapeutics share price has underperformed the S&P500 Index by -33.48% over the past year.
What are the analyst and broker recommendations for Lisata Therapeutics?
The overall consensus recommendation for Lisata Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lisata Therapeutics dividend yield?
Lisata Therapeutics does not currently pay a dividend.
Does Lisata Therapeutics pay a dividend?
Lisata Therapeutics does not currently pay a dividend.
When does Lisata Therapeutics next pay dividends?
Lisata Therapeutics does not currently pay a dividend.
How do I buy Lisata Therapeutics shares?
To buy shares in Lisata Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lisata Therapeutics?
As of the previous close price of $2.10, shares in Lisata Therapeutics had a market capitalisation of $18.06m.
Where are Lisata Therapeutics shares listed?
Here are the trading details for Lisata Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LSTA
What kind of share is Lisata Therapeutics?
Based on an overall assessment of its quality, value and momentum Lisata Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lisata Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Lisata Therapeutics is $16.67. That is 693.81% above the last closing price of $2.10.
Analysts covering Lisata Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.19 for the next financial year.
Find out moreWhat is the trend in the Lisata Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lisata Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -23.48%.
As of the last closing price of $2.10, shares in Lisata Therapeutics were trading -24.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lisata Therapeutics PE Ratio?
The Lisata Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lisata Therapeutics?
Lisata Therapeutics' management team is headed by:
- Gregory Brown - NEC
- David Mazzo - PRE
- Todd Girolamo - SVP
- William Sietsema - VPR
- Michael Davidson - IND
- Steven Klosk - IND
- Steven Myers - IND
- Cynthia Schwalm - IND
- Peter Traber - IND
- Anne Whitaker - IND